Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Relapsing-remitting

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    297 result(s) found for: Relapsing-remitting. Displaying page 5 of 15.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-005985-35 Sponsor Protocol Number: 1206.15 Start Date*: 2006-08-29
    Sponsor Name:Boehringer Ingelheim
    Full Title: A 24 week, MRI based, double-blind, randomised, placebo-controlled, modified dose-escalation trial to evaluate the safety, efficacy and pharmacokinetics of BIRT 2584 XX tablets at doses of 100, 300...
    Medical condition: Relapsing forms of Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002785-20 Sponsor Protocol Number: EVIDIMS Start Date*: 2011-09-19
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis
    Medical condition: Multiple Sclerosis and Clinical isolated Syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015556-15 Sponsor Protocol Number: 101MS325 Start Date*: 2010-05-07
    Sponsor Name:Biogen Idec Limited
    Full Title: A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects wit...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) PT (Completed) HU (Prematurely Ended) NL (Prematurely Ended) SI (Prematurely Ended) LV (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002633-20 Sponsor Protocol Number: A4M105038 Start Date*: 2006-11-17
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice dail...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) FI (Completed) FR (Completed) AT (Completed) IT (Completed) LT (Prematurely Ended) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-015318-23 Sponsor Protocol Number: 205MS203 Start Date*: 2010-01-21
    Sponsor Name:Biogen Idec Ltd.
    Full Title: A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Efficacy of Daclizumab High Yield Process (DAC HYP) Monotherapy in Subjects with Multiple Sclerosis Who Have Complete...
    Medical condition: Relapsing-remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-005559-46 Sponsor Protocol Number: 205MS202 Start Date*: 2009-01-23
    Sponsor Name:Biogen Idec Ltd.
    Full Title: A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT)
    Medical condition: Relapsing-remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005008-24 Sponsor Protocol Number: 08126 Start Date*: 2011-07-07
    Sponsor Name:University of Nottingham
    Full Title: Worms for immune regulation of multiple sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    13.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-007549-29 Sponsor Protocol Number: 2008-229 Start Date*: 2009-06-09
    Sponsor Name:Danish Multiple Sclerosis Research Center
    Full Title: Trichuris suis Ova Therapy for Relapsing Multiple Sclerosis - a safety study
    Medical condition: Relapsing Multipel Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10028245 Multiple sclerosis LLT
    12.0 10063399 Relapsing-remitting multiple sclerosis LLT
    12.0 10053395 Progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000253-92 Sponsor Protocol Number: EHP-101-MS02 Start Date*: 2022-10-14
    Sponsor Name:Emerald Health Pharmaceuticals Inc.
    Full Title: A Phase IIa, Open-label, Multicentre Dose-Finding Trial in Patients with Relapsing Forms of Multiple Sclerosis (RMS) to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101
    Medical condition: Relapsing Forms of Multiple Sclerosis (RMS)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001166-29 Sponsor Protocol Number: inims-009 Start Date*: 2020-03-18
    Sponsor Name:University Medical Centre Hamburg-Eppendorf
    Full Title: A randomised controlled trial to compare ocrelizumab or alemtuzumab with autologous hematopoietic stem cell transplantation (aHSCT) in high inflammatory multiple sclerosis (COAST)
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023560-40 Sponsor Protocol Number: STU00010022 Start Date*: 2011-03-23
    Sponsor Name:Uppsala l�ns landsting
    Full Title: Haematopoetic Stem Cell Therapy for Patients with Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study
    Medical condition: Relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004061-41 Sponsor Protocol Number: 101-MS-321 Start Date*: 2006-06-01
    Sponsor Name:BIOGEN IDEC LTD
    Full Title: An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o...
    Medical condition: Multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Prematurely Ended) FI (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) HU (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-005117-41 Sponsor Protocol Number: ICP-CL-00112 Start Date*: 2021-06-30
    Sponsor Name:InnoCare Pharma, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Orelabrutinib in Patients with Relapsing-Remitting Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, a...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002820-10 Sponsor Protocol Number: 205MS305 Start Date*: 2017-03-13
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) Switching from Nataliz...
    Medical condition: Remitting-Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012989-30 Sponsor Protocol Number: MS-LAQ-301E Start Date*: 2009-11-17
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-301 (ALLEGRO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral la...
    Medical condition: Laquinimod is developed for the treatment of relapsing remitting multiple sclerosis.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) NL (Prematurely Ended) EE (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended) FR (Completed) LT (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-006338-32 Sponsor Protocol Number: WA21493 Start Date*: 2008-05-06
    Sponsor Name:Hoffman La Roche Ltd
    Full Title: Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do...
    Medical condition: Relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) ES (Completed) CZ (Completed) SK (Completed) DK (Completed) BE (Completed) NL (Completed) FI (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002082-19 Sponsor Protocol Number: LAQ-MS-306 Start Date*: 2013-11-25
    Sponsor Name:Teva Pharmaceutical Industries, Ltd.
    Full Title: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate the Efficacy, Safety and Tolerability of 2 Doses of Oral administration of...
    Medical condition: Relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) SE (Prematurely Ended) FI (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000888-27 Sponsor Protocol Number: GTR001 Start Date*: 2011-09-21
    Sponsor Name:Synthon BV
    Full Title: Multi-centre, randomized, double-blind, placebo-controlled, parallel-group, 9 month, equivalence trial comparing the efficacy and safety and tolerability of GTR (Synthon BV) to Copaxone® (Teva) in ...
    Medical condition: Relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) GB (Completed) DE (Completed) EE (Completed) GR (Prematurely Ended) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-007057-42 Sponsor Protocol Number: A4M108119 Start Date*: 2007-05-29
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An open-label study of leukocyte counts in the cerebrospinal fluid and blood of subjects with relapsing forms of multiple sclerosis following treatment with firategrast
    Medical condition: relapsing forms of multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    9.1 10063400 Secondary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) CZ (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-013333-24 Sponsor Protocol Number: EMR 701048-525 Start Date*: 2009-08-03
    Sponsor Name:MERCK SERONO SPA
    Full Title: Multicenter, open-label, 12 weeks Phase IV study to assess adherence to treatment in relapsing multiple sclerosis (RMS) subjects switching from other injectable DMDs using ReBiSmart to self-inje...
    Medical condition: RELAPSING MULTIPLE SCLEROSIS
    Disease: Version SOC Term Classification Code Term Level
    12.0 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 11 03:40:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA